Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration

BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during prolonged anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 10 vom: 17. Okt., Seite 546-552
1. Verfasser: Richardson, Quintin R (VerfasserIn)
Weitere Verfasser: Zhang, Youning, Deiner, Michael S, Wang, Suling T, Bhisitkul, Jonah M, Arnold, Benjamin F, Bhisitkul, Robert B
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Angiogenesis Inhibitors Endothelial Growth Factors Vascular Endothelial Growth Factor A Ranibizumab ZL1R02VT79
LEADER 01000naa a22002652 4500
001 NLM347547168
003 DE-627
005 20231226034101.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20220914-01  |2 doi 
028 5 2 |a pubmed24n1158.xml 
035 |a (DE-627)NLM347547168 
035 |a (NLM)36239676 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Richardson, Quintin R  |e verfasserin  |4 aut 
245 1 0 |a Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.10.2022 
500 |a Date Revised 22.12.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during prolonged anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited 
520 |a MATERIALS AND METHODS: This is a retrospective review of nAMD patients receiving anti-VEGF therapy for ≥ 5 years. Near-infrared reflectance images and vision data were extracted every 6 months. MA lesion areas were measured using ImageJ 
520 |a RESULTS: Vision showed a mean decline of -1.2 letters/year. Eyes with MA showed a greater decrease of -1.6 letters/year compared to eyes without MA (-0.7 letters/year). Cumulative incidence of MA was 38% at 5 years. MA was significantly associated with declining vision, showing a -0.7 letter decrease for every 1 mm2 increase in lesion size 
520 |a CONCLUSION: Over a 5-year course of nAMD treatment, MA affected most eyes, and MA progression was significantly associated with vision decline. [Ophthalmic Surg Lasers Imaging Retina 2022;53:546-552.] 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Research Support, N.I.H., Extramural 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Endothelial Growth Factors  |2 NLM 
650 7 |a Vascular Endothelial Growth Factor A  |2 NLM 
650 7 |a Ranibizumab  |2 NLM 
650 7 |a ZL1R02VT79  |2 NLM 
700 1 |a Zhang, Youning  |e verfasserin  |4 aut 
700 1 |a Deiner, Michael S  |e verfasserin  |4 aut 
700 1 |a Wang, Suling T  |e verfasserin  |4 aut 
700 1 |a Bhisitkul, Jonah M  |e verfasserin  |4 aut 
700 1 |a Arnold, Benjamin F  |e verfasserin  |4 aut 
700 1 |a Bhisitkul, Robert B  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 53(2022), 10 vom: 17. Okt., Seite 546-552  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnns 
773 1 8 |g volume:53  |g year:2022  |g number:10  |g day:17  |g month:10  |g pages:546-552 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20220914-01  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
951 |a AR 
952 |d 53  |j 2022  |e 10  |b 17  |c 10  |h 546-552